Short answer
Praxis Precision Medicines, Inc. (PRAX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$93M
- −33.6% YoY
- EPS (diluted)
- −$3.20
- +2.7% YoY
Source: XBRL data from the Praxis Precision Medicines, Inc. (PRAX) Q1 2026 10-Q on SEC EDGAR. USD.
Praxis Precision Medicines, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales since inception
- Net loss $92.6M vs $69.3M YoY; operating margin not applicable due to zero revenue
- Cerebrum R&D $52.0M, largest platform; Solidus R&D $4.3M, smallest platform
- Cash, equivalents and marketable securities $1.4B; operating cash use $86.2M vs $53.0M YoY
- January offering generated $621.2M net; funding expected through 2028, with expenses projected to increase significantly
Risk Factors
- No material changes from 2025 Form 10-K risk factors
- Regulatory and compliance risks carried forward from the 10-K
- Clinical-development and regulatory-approval risks carried forward from the 10-K
- Liquidity and additional-capital requirements carried forward from the 10-K
- Competitive and market risks carried forward from the 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Praxis Precision Medicines, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.